 |
PDBsum entry 6vxx
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
6vxx
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Viral protein
|
|
|
Title:
|
|
Structure of the sars-cov-2 spike glycoprotein (closed state)
|
|
Structure:
|
|
Spike glycoprotein. Chain: a, b, c. Fragment: ectodomain. Synonym: s glycoprotein,e2,peplomer protein,sars-cov-2 spike glycoprotein. Engineered: yes
|
|
Source:
|
|
Severe acute respiratory syndrome coronavirus 2. 2019-ncov. Organism_taxid: 2697049. Gene: s, 2. Expressed in: homo sapiens. Expression_system_taxid: 9606
|
|
Authors:
|
|
A.C.Walls,Y.J.Park,M.A.Tortorici,A.Wall,Seattle Structural Genomics Center For Infectious Disease (Ssgcid),A.T.Mcguire,D.Veesler
|
|
Key ref:
|
|
A.C.Walls
et al.
(2020).
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Cell,
181,
281.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
25-Feb-20
|
Release date:
|
11-Mar-20
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
P0DTC2
(SPIKE_SARS2) -
Spike glycoprotein from Severe acute respiratory syndrome coronavirus 2
|
|
|
|
Seq:
Struc:
|
|
|
|
1273 a.a.
972 a.a.*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
|
*
PDB and UniProt seqs differ
at 2 residue positions (black
crosses)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Cell
181:281
(2020)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
|
|
A.C.Walls,
Y.J.Park,
M.A.Tortorici,
A.Wall,
A.T.McGuire,
D.Veesler.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000
deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the
main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells
and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with
similar affinities to human ACE2, correlating with the efficient spread of
SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a
furin cleavage site at the boundary between the S1/S2
subunits, which is processed during biogenesis and sets this virus apart from
SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the
SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of
vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S
murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into
cells, indicating that cross-neutralizing antibodies targeting conserved S
epitopes can be elicited upon vaccination.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
');
}
}
|
Links
